Single‐cell mass cytometry adapted to measurements of the cell cycle

Gregory K. Behbehani1, Sean C. Bendall2, Matthew R. Clutter2, Wendy J. Fantl2, Garry P. Nolan2
1Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
2Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA

Tóm tắt

Abstract

Mass cytometry is a recently introduced technology that utilizes transition element isotope‐tagged antibodies for protein detection on a single‐cell basis. By circumventing the limitations of emission spectral overlap associated with fluorochromes utilized in traditional flow cytometry, mass cytometry currently allows measurement of up to 40 parameters per cell. Recently, a comprehensive mass cytometry analysis was described for the hematopoietic differentiation program in human bone marrow from a healthy donor. The current study describes approaches to delineate cell cycle stages utilizing 5‐iodo‐2‐deoxyuridine (IdU) to mark cells in S phase, simultaneously with antibodies against cyclin B1, cyclin A, and phosphorylated histone H3 (S28) that characterize the other cell cycle phases. Protocols were developed in which an antibody against phosphorylated retinoblastoma protein (Rb) at serines 807 and 811 was used to separate cells in G0 and G1 phases of the cell cycle. This mass cytometry method yielded cell cycle distributions of both normal and cancer cell populations that were equivalent to those obtained by traditional fluorescence cytometry techniques. We applied this to map the cell cycle phases of cells spanning the hematopoietic hierarchy in healthy human bone marrow as a prelude to later studies with cancers and other disorders of this lineage. © 2012 International Society for Advancement of Cytometry

Từ khóa


Tài liệu tham khảo

10.1016/j.jim.2005.09.020

10.1039/b710510j

10.1021/ac901049w

10.1126/science.1198704

10.1038/nbt.1991

Griffin J, 1986, Clonogenic cells in acute myeloblastic leukemia, Blood, 68, 1185–1195, 10.1182/blood.V68.6.1185.1185

Moore MA, 1974, Agar culture studies in 127 cases of untreated acute leukemia: The prognostic value of reclassification of leukemia according to in vitro growth characteristics, Blood, 44, 1–18, 10.1182/blood.V44.1.1.1

Raza A, 1997, Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo‐ and/or bromodeoxyuridine, Exp Hematol, 25, 530

Pearce DJ, 2006, AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML, Blood, 107, 1166–1173, 10.1182/blood-2005-06-2325

10.1186/1471-2105-10-106

10.1002/0471142956.cy1017s53

van Lochem EG, 2004, Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts, Cytometry Part B: Clinical Cytometry, 60, 1–13

10.1021/ac702128m

10.1002/cyto.a.20252

10.1016/S0092-8674(04)00300-9

10.1002/(SICI)1097-0320(19960901)25:1<1::AID-CYTO1>3.0.CO;2-N

10.1002/0471142956.cy0724s28

10.1007/978-1-61737-950-5_11

10.1046/j.1356-9597.2001.00498.x

10.1369/jhc.4A6285.2004

10.1002/0471142956.cy0703s30

10.1089/scd.2007.0017

10.2353/ajpath.2006.060312

10.1002/cyto.a.20003

10.1158/1078-0432.CCR-09-0787

2011, Asymmetric cancer cell division regulated by AKT, Proc Natl Acad Sci, 108, 12845–12850

Gong J, 1994, Unscheduled expression of Cyclin B1 and Cyclin E in several leukemic and solid tumor cell lines, Cancer Res, 54, 4285–4288

10.1101/sqb.2008.73.031

10.1073/pnas.96.6.3120

Passegue E, 2005, Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates, J Exp Med, 202, 1599–1611, 10.1084/jem.20050967

Head DR, 2011, Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis, Bone Marrow Res, 2011

Preisler H, 1980, Prediction of response to chemotherapy in acute myelocytic leukemia, Blood, 56, 361–367, 10.1182/blood.V56.3.361.361